Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis

Novartis (VTX: NOVN) announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx^® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis. The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients.The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.

As quoted in the press release:

“This is an important label update for Cosentyx, the first IL-17A inhibitor approved for moderate-to-severe plaque psoriasis. It confirms the additional value Cosentyx offers to patients who seek a treatment effective in various areas of the body,” said Eric Hughes, Global Development Unit Head, Immunology & Dermatology. “We’re proud to expand treatment possibilities of Cosentyx for an even greater number of patients.”

Click here to read the full press release.